CalciMedica Inc. (NASDAQ:CALC) Short Interest Up 770.0% in January

CalciMedica Inc. (NASDAQ:CALC) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 699,828 shares, an increase of 770.0% from the January 15th total of 80,437 shares. Based on an average daily volume of 5,279,084 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.3% of the shares of the company are short sold. Approximately 8.3% of the shares of the company are short sold. Based on an average daily volume of 5,279,084 shares, the days-to-cover ratio is presently 0.1 days.

CalciMedica Price Performance

CALC traded up $0.08 during midday trading on Tuesday, hitting $0.74. The stock had a trading volume of 827,230 shares, compared to its average volume of 2,291,308. CalciMedica has a 1 year low of $0.52 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The business has a fifty day moving average of $4.59 and a 200 day moving average of $3.66. The company has a market cap of $10.62 million, a P/E ratio of -0.45 and a beta of 0.49.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.02. As a group, equities analysts forecast that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CALC. Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. Finally, Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research report on Saturday, January 17th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $16.00.

Institutional Investors Weigh In On CalciMedica

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CALC. PVG Asset Management Corp purchased a new stake in shares of CalciMedica during the fourth quarter worth about $302,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in CalciMedica in the 3rd quarter worth approximately $165,000. Meritage Portfolio Management grew its position in shares of CalciMedica by 33.8% in the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock worth $189,000 after buying an additional 15,539 shares during the last quarter. Sheets Smith Investment Management bought a new position in shares of CalciMedica during the third quarter valued at approximately $157,000. Finally, Cetera Investment Advisers boosted its holdings in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares in the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.